Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
Helix Biopharma Corp. Announces Board Composition Changes
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM
Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting
Helix Biopharma Corp. Announces Publication in Frontiers in Oncology on the Effects of L-DOS47 as Monotherapy in NSCLC
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Nine Month Period Ended April 30, 2025
Helix BioPharma Corp. Announces CFO Appointment to Support Strategic Growth and Upcoming Milestones
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group
Helix BioPharma Corp. (HBP.TO) Signs Capital Raising Agreement with Kerentech Consulting Ltd.
Helix BioPharma Corp. Appoints New COO and Communications Director to Accelerate Growth and Deliver on its Mission Against Hard-to-Treat Cancers
Helix BioPharma Corp. Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan
Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three and Six Month Periods Ended January 31, 2025
Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
Helix Biopharma Corp. Expands Leadership Team with World-Class Oncology and Scientific Experts
Helix BioPharma Corp. receives approval for the Extension of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing
Helix BioPharma Corp. Extends Date of Annual General and Special Meeting to Seek Approval of Asset Acquisitions and Proposed Financing